In a report released on September 29, Andrew Berens from Leerink Partners maintained a Buy rating on BridgeBio Oncology Therapeutics. The company’s shares closed yesterday at $12.44.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Berens covers the Healthcare sector, focusing on stocks such as AstraZeneca, Celcuity, and Agios Pharma. According to TipRanks, Berens has an average return of 5.6% and a 44.42% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for BridgeBio Oncology Therapeutics with a $24.00 average price target, a 92.93% upside from current levels. In a report released on September 15, H.C. Wainwright also initiated coverage with a Buy rating on the stock with a $27.00 price target.
The company has a one-year high of $12.88 and a one-year low of $8.50. Currently, BridgeBio Oncology Therapeutics has an average volume of 220.7K.
Read More on BBOT:
Disclaimer & DisclosureReport an Issue
- BridgeBio Oncology initiated with an Outperform at Leerink
- BridgeBio Oncology initiated with a Buy at H.C. Wainwright
- BridgeBio Oncology initiated with an Outperform at Oppenheimer
- BridgeBio Oncology initiated with an Overweight at Piper Sandler
- BridgeBio Oncology initiated with an Overweight at Cantor Fitzgerald
/Jen-Hsun%20Huan%20NVIDIA's%20Founder%2C%20President%20and%20CEO%20by%20jamesonwu1972%20via%20Shutterstock.jpg)